Abstract. MicroRNAs (miRNAs) negatively regulate the expression of the target genes by binding to ʻseed sequences' in the 3'-untranslated region (3'-UTR) mRNA transcripts, and the variants within or nearby ʻseed sequences' may compromise or enhance miRNA/mRNA interaction leading to either ʻloss-of-function' or ʻgain-of-function' effects. Cataracts are the leading cause of blindness worldwide and are characterized by progressive aggregation and precipitation of lens proteins, and the development of age-related cataracts is associated with dysregulated cellular activities of lens epithelial cells. Luciferase assays and online miRNA databases were used to validate that tumor protein p53 (TP53) is the target gene of miR-125b. Furthermore, reverse transcription-quantitative polymerase chain reaction and western blotting were conducted to detect expression levels of miR-125b and TP53 in different groups of cells transfected with miR-125b mimics or inhibitors. In addition, flow cytometry analysis and the MTT assay were conducted to detect the effects of miR-125b on apoptosis and cell viability. The current study demonstrated that the rs78378222 polymorphism minor allele introduces a novel potential miR-125b binding site in the TP53 3'-UTR with a consecutive 8-bp perfect match, creating a ʻgain-of-function' variant and affecting the regulation of TP53 expression. A luciferase assay demonstrated that transfection of lens epithelial cells with wild type TP53 3'-UTR significantly reduced the luciferase activity of the miR-125b overexpressing cells compared with scramble controls. In addition, the luciferase activity of miR-125b overexpressing cells transfected with the construct containing the rs78378222 polymorphism minor allele was also reduced compared with cells transfected with the wild type 3'-UTR. Furthermore, it was demonstrated that the expression level of miR-125 was comparable in epithelial cells from patients with age-associated cataracts and controls, whereas the expression level of TP53 was significantly higher in the cataract group compared with controls. Additionally, transfection with 50 nM miR-125b mimics markedly reduced the mRNA and protein expression levels of TP53 in the cultured lens epithelial cells, and miR-125b significantly induced apoptosis in the epithelial cells compared with negative control cells. In conclusion, TP53 was identified as a target of miR-125b, and the minor allele of the rs78378222 polymorphism promoted the miR-125b/TP53 mRNA interaction.
Introduction
Cataracts are a typical age-correlated condition and the leading cause of visual loss worldwide (1) . Previous studies have demonstrated that age-correlated cataracts cause approximately half of all cases of visual loss (2) (3) (4) . A previous epidemiological study demonstrated that 96% of people aged >60 years have different types or severities of lens opacity (5) . According to estimates by the World Health Organization, the number of people with cataract blindness worldwide will reach 40 million by 2025 (6) . Age-correlated cataracts cause severe visual impairment, reduce quality of life, and become a burden on social economy and health resources. As an important component of the visual refraction system, human lenses are relatively isolated tissues surrounded by the vitreous body and the aqueous humor. Lenses, which are transparent in younger individuals, change with age. These changes begin with the development of a compact, hard nucleus and regional opacity, which result in the occurrence of pathological cataracts.
MicroRNAs (miRNAs), a class of endogenous small non-coding RNAs of 20-25 nucleotides, modulate the expression of genes at the post-transcriptional level (7) . miRNAs bind to complementary sequences present in the 3'-untranslated regions (3'-UTR) of target gene mRNAs and, thus, regulate translational interference or degradation of mRNAs (8) . Several miRNAs have previously been detected rs78378222 polymorphism in the 3'-untranslated region of TP53 contributes to development of age-associated cataracts by modifying microRNA-125b-induced apoptosis of lens epithelial cells in animal eyes (9, 10) ; miRNA-31 (miRNA-31), miR-184, miR-204, miR-125b, miR-26a, let-7b and others were identified in the lens; miR-26a, miR-24, miR-31 miR-184 and miR-205 were identified in the cornea; and miR-181a, miR-124a, miR-182, miR-183, miR-125b and miR-30 were demonstrated to be produced in the retina (9, 10) . Accumulating evidence has demonstrated that abnormal expression of miRNAs is closely correlated with the pathogenesis of a wide range of age-associated conditions (11) (12) (13) (14) , including as cataracts (15) . miRNA studies have provided novel insights to the treatment of such diseases (16, 17) . Variants in primary miRNAs or in the 3'-UTR of the target gene may interfere with the production of the miRNA or the binding between miRNA and mRNA of the target gene. miRNAs negatively regulate the expression of target genes by binding to the ʻseed sequence' in the 3'-UTR of the genes, and the variants within or nearby the seed sequence may inhibit or enhance miRNA/mRNA interaction leading to either ʻloss-of-function' or ʻgain-of-function'. The present study investigated the potential effect of the rs78378222 polymorphism (18, 19) in the 3'-UTR of tumor protein p53 (TP53) on the miR-125b-induced apoptosis of lens epithelial cells, and the association between the rs78378222 polymorphism and the risk of age-associated cataracts.
Materials and methods
Study population. Lens epithelial cells were collected as previously described (20) from 12 patients with cataracts and 12 normal controls receiving eye surgery at Beijing Tongren Hospital (Beijing, China). The study protocol followed the guidelines of the Declaration of Helsinki (21) and was approved by the institutional review board of Beijing Tongren Hospital. Following a full explanation of the surgical procedures and possible complications, all patients provided written informed consent. Patients were selected based on clinically observable nuclear cataracts of grade 2 or 3 according to the Lens Opacities Classification System III (22) . Exclusion criteria included cataract hardness greater than grade 3. Patients with type 1 diabetes mellitus (DM), rheumatologic disease and other systemic diseases, with the exception of type 2 DM, were also excluded. SRA01/04 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 100 mg/ml streptomycin, 100 U/ml penicillin and 10% fetal calf serum (Invitrogen; Thermo Fisher Scientific, Inc.) in a humidified atmosphere of 5% CO 2 at 37˚C.
DNA sequencing and cell biology.
A DNA extraction kit (Qiagen, Inc., Valencia, CA, USA) was used to extract genomic DNA from patient lens cells. The Sanger method was used to bidirectionally sequence the TP53 3'-UTRs (Beijing Tongren Hospital). A TP53 reference sequence (NM_000546.5; genome.ucsc.edu) was compared with all sequences and used to determine the genotype of the polymorphism.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from cataractous lens samples and cultured SRA01/04 epithelial cells according to the manufacturer's instructions. A UV-Vis spectrophotometer (UV-1800; Shimadzu Corporation, Kyoto, Japan) was used to determine the quality of RNA. Agarose gel (1.5%) electrophoresis with 260/280 values between 1.8 and 2.0 was used to confirm RNA integrity. PrimerScript RT reagent kit (Takara Biotechnology Co., Ltd., Dalian, China) was used produce cDNA from 1 ng RNA for RT-qPCR analysis. An ABI 7500 cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.), RT primer and TaqMan probes (Guangzhou RiboBio Co., Ltd., Guangzhou, China) were used to determine the expression of miR-125b and TP53. RNA U6 small nuclear 2 was used as the endogenous reference control. The conditions for the RT reaction were 65˚C for 5 min, 25˚C for 10 min, 42˚C for 1 h and 75˚C for 10 min. The PCR cycling conditions were as follows: 95˚C for 5 min; 40 cycles of 95˚C for 10 sec, and 60˚C for 1 min. RT-qPCR analysis was performed twice on three independent specimens. The primer (Shanghai Jieli Biotechnology Co., Ltd., Shanghai, China) sequences were as follows: Forward, 5'-TCA GTT TGC TGT TCT GGGTG-3' and reverse, 5'-CGG TTG GCT GGA AAG GAG-3' for GAPDH; forward, 5'-CCC CTC TGA GTC AGG AAACA-3' and reverse, 5'-AGA CAG AAG GGC CTG ACTCA-3' for TP53; forward, 5'-TCA GTT TGC TGT TCT GGGTG-3' and reverse, 5'-CGG TTG GCT GGA AAG GAG-3' for U6; and forward, 5'-UCC CUG AGA CCC UAA CUU GUGA-3' and reverse, 5'-ACA AGU UAG GGU CUC AGG CACU-3' for miR-125b. The equation RQ=2 -ΔΔCq was used to calculate the relative abundance of miR-125b and TP53 mRNA in cell lines and tissues (23) . GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) was used to produce graphs and perform analyses.
Luciferase assay. Human genomic DNA was used for amplification of the 3'-UTR of the TP53 gene containing conserved binding sites for miR-125b. Following amplification, the fragments were implanted into the pmiR-RB-REPORT vector (Guangzhou RiboBio Co., Ltd.). A mutant 3'-UTR fragment containing mutations in seed binding sites was obtained using a QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA), according to the manufacturer's protocols, to introduce deletions in the 3'-UTR of TP53. Similarly, the TP53-3'-UTR mutant fragment was inserted into the same sites of the pmiR-RB-REPORT control vector. For reporter assays, SRA01/04 cells were plated in 24-well plates and cultured overnight in Iscove's modified Dulbecco's medium (Invitrogen; Thermo Fisher Scientific, Inc.). Following incubation, the cells were cotransfected with miR-125b mimic/mimic control and wild-type/mutant reporter plasmid (Guangzhou RiboBio Co., Ltd.) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h post-transfection, the Dual-Luciferase Reporter assay system (Promega Corporation, Madison, WI, USA) was used to determine luciferase activity according to the manufacturer's protocol. The GloMax™ 96 Microplate Luminometer (Promega Corporation) was used to measure luciferase activity. The endogenous control was Renilla luciferase plasmid. Each experiment was conducted with three independent specimens and repeated twice.
Apoptosis analysis. At 48 h following transfection, an apoptosis assay was performed on SRA01/04 lens epithelial cells (1.5x10 5 cells/well). An apoptosis detection kit (Nanjing KeyGen Biotech. Co. Ltd., Nanjing, China) was used to determine apoptosis using Annexin V/propidium iodide staining. The specimens were cultured at room temperature for 15 min in darkness and analyzed by flow cytometry (BD Influx™ Cell Sorter; BD Biosciences, Franklin Lakes, NJ, USA). CellQuest software (BD Biosciences) was used to analyze the results.
Western blot analysis. Protein extraction from SRA01/04 and primary cells was performed by incubation with lysis buffer containing 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 2 mg/ml aprotinin, 1 mM phenylmethane sulfonyl fluoride and 150 mM NaCl at 4˚C for 30 min. A BCA Protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to quantify the protein levels. The separation of protein extracts (20 µg) was performed via 10% SDS-polyacrylamide gel electrophoresis (Roche Applied Science, Penzberg, Germany) and transferred onto polyvinylidene difluoride membranes (PerkinElmer, Inc., Waltham, MA, USA). Membranes were blocked in Tris-buffered saline containing 0.05% Tween 20 (TBST; BioSharp, Hefei, China) with 5% non-fat milk, 2.7 mmol/l KCl, 137 mmol/l NaCl and 25 mmol/l Tris-HCl (pH 7.5) at 37˚C for 1 h. The membranes were then incubated with primary antibodies, mouse monoclonal against β-actin (1:8,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-47778) or rabbit polyclonal against TP53 (1:3,000; Santa Cruz Biotechnology, Inc.; cat. no. 6243) in TBST with 5% non-fat milk at 4˚C overnight. Following washes with TBST three times, membranes were cultured with horseradish peroxidase-conjugated goat anti-rabbit polyclonal (1:15,000; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. Q11402MP) Statistical analysis. The differences in microarray data were compared between the two groups using the P-values corrected by false discovery rate, which were below 0.05 obtained by significant analysis of microarrays software (statweb.stanford.edu/~tibs/SAM/). SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA) and an independent samples t-test were used to estimate differences between two groups. P<0.05 was considered to indicate a statistically significant difference.
Results

Effect of rs78378222 on the binding site in the 3-UTR of TP53
. miRNAs negatively regulate the expression of target genes by binding to the ʻseed sequence' in the gene 3'-UTR. Variants within or nearby the ʻseed sequences' may compromise or enhance miRNA/mRNA interaction leading to either ʻloss-of-function' or ʻgain-of-function' effects. The present study evaluated the potential effect of the rs78378222 polymorphism in the 3'-UTR of TP53 on miRNA-125b-induced apoptosis of lens epithelial cells, and the association between the rs78378222 polymorphism and the risk of age-associated cataracts. Initially, sequences of mature miR-125b and TP53 (wild-type and polymorphic) were analyzed and compared. As presented in Fig. 1 , replacement of A with C (at position 1177) introduces a novel potential binding site in the 3'-UTR of TP53 with consecutive 8-bp perfect match, indicating that the rs78378222 polymorphism results in a ʻgain-of-function' to regulate TP53 expression.
Effect of rs78378222 on TP53 expression. To examine the effect of the rs78378222 polymorphism on TP53 expression, the full length TP53 3'-UTR was subcloned and inserted into a pcDNA3 vector containing a firefly luciferase gene downstream, and the minor allele of the rs78378222 polymorphism (C) was introduced. The results of the luciferase assay demonstrated that transfection with wild type TP53 3'-UTR (A) significantly reduced the luciferase activity of the miR-125b overexpressing cells, compared with the scramble controls. 
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Furthermore, the miR-125b overexpressing cells transfected with the construct containing the minor allele of rs78378222 polymorphism (C) was reduced further than those transfected with wild type 3'-UTR, suggesting miR-125 negatively regulates the expression of TP53 by targeting the 3'-UTR of the gene (P<0.01; Fig. 2) , and introduction of a novel binding site caused by the rs78378222 polymorphism further promoted the negative regulatory association between miR-125 and TP53.
mRNA levels of miR-125b and TP53. To further confirm this hypothesis, epithelial cells were collected from patients with age-associated cataracts and controls, and the mRNA expression levels of miR-125b and TP53 were determined. As demonstrated in Fig. 3 , the expression level of miR-125b was comparable between the two groups, whereas the mRNA expression level of TP53 was significantly higher in the cataract group compared with the control (P<0.01). Additionally, the expression of TP53 protein was determined using western blot analysis (Fig. 4) . The target bands were quantified by analyzing their relative density, which demonstrated that the protein expression level of TP53 was significantly higher in the cataract cases compared with the control group (P<0.01; Fig. 4) .
Regulatory association between miR-125b and TP53.
To further investigate the regulatory association between miR-125b and TP53, miR-125b mimics were transfected into cultured SRA01/04 epithelial cells. Transfection with 25 nM mimics was not identified to significantly alter the expression of TP53; however, 50 nM miR-125b mimics substantially reduced the mRNA and protein expression levels of TP53 in the lens epithelial cells (P<0.01; Fig. 5 ). Additionally, compared with negative controls, miR-125b (50 nM) significantly induced apoptosis in the epithelial cells (Fig. 6 ).
Discussion
Previous investigation demonstrated that miRNAs are an important group of gene regulators. The complete miRNA transcriptome in human lens cells is unclear, although miRNAs have been detected in a variety of mammalian organs and tissues, including the eyes. To the best of our knowledge, the present study is the first to investigate miRNAs in the central epithelium of cataractous and transparent human lens. Determining the mutations that lead to the development of age-associated cataracts may improve understanding of the mechanisms that mediate cataractogenesis, and provide novel insights into the development and physiology of the normal lens. Furthermore, functional analysis of candidate variants is a critical measure to understand the molecular defects involved in age-associated cataracts, which has a strong genetic component to its etiology. This may aid in elucidating novel therapeutic strategies to delay lens opacification. The present study evaluated the potential effect of TP53 3'-UTR rs78378222 on the miR-125b-induced apoptosis of lens epithelial cells, and the association between the rs78378222 polymorphism and the risk of the development of age-associated cataracts. Initially, the sequences of mature miR-125b and TP53 (wild-type and polymorphic) were analyzed and compared. Replacement of A with C introduces a novel potential binding site in the 3'-UTR of TP53 with a consecutive 8-bp perfect match, indicating that the rs78378222 polymorphism creates a ʻgain-of-function' effect to regulate TP53 expression via miR-125b.
As a highly conserved miRNA expressed throughout an array of species ranging from nematode to human, miR-125b acts as either a repressor or promoter of gene expression, and is associated with various diseases (24) . By acting on a range of different transcription factors (25) , growth factors (26) and matrix metalloproteinases (27, 28) , miR-125b is important for various cellular processes, including cell proliferation, differentiation and apoptosis. The current study identified TP53 as a target of miR-125b, and replacement with the rs78378222 polymorphism minor allele (C) significantly promoted interaction between the miR-125b and TP53 mRNA, as demonstrated by a luciferase assay. Furthermore, the present study demonstrated that transfection of lens epithelial cells with 25 nM mimics did not significantly alter the expression of TP53, whereas 50 nM miR-125b mimics significantly reduced the mRNA and protein expression level of TP53 in the lens epithelial cells compared with negative control miRNA.
TP53 is a well-studied pro-apoptotic protein in vivo. Prior to 2011, no genome-wide association study had demonstrated a significant correlation between any cancer and a TP53 polymorphism germline (other than variants of Li-Fraumeni syndrome) (29) . The rs78378222 TP53 polymorphism was previously demonstrated to be significantly associated with breast cancer (30) . An independent study confirmed that rs78378222 was correlated with a 3.5-fold higher risk of glioma development (31). Stacey et al (32) demonstrated that the transcript levels of TP53 expressed by rs78378222 [A/C] heterozygotes was lower than that in wild type homozygotes in human blood samples. rs78378222 is located in the fifth nucleotide of the TP53 polyadenylation signal and was initially hypothesized to be required for a wide range of processes, including polyadenylation machinery recognition, cleavage, polyadenylation and transport of mature mRNAs to the cytoplasm. The current study demonstrated that replacement with C in the sequence introduces a novel potential miRNA binding site in the TP53 3'-UTR, with a consecutive 8-bp perfect match, indicating that rs78378222 creates a ʻgain-of-function' effect. miR-125 is another important regulator of TP53, and the minor allele (C) of the rs78378222 polymorphism ʻgenerates' a novel perfect match binding site for miR-125b in the 3'-UTR of TP53. Additionally, the present study demonstrated that the expression level of miR-125b was comparable in epithelial cells from patients with cataracts and controls, whereas the mRNA expression level of TP53 was significantly higher in the cataract group compared with the controls, suggesting that the polymorphism significantly promotes interaction between miR-125b and TP53.
In conclusion, the current study demonstrated that the minor allele (C) of the rs78378222 polymorphism introduces a potential novel miR-125b binding site in the 3'-UTR of TP53, with a consecutive 8-bp perfect match, indicating that the rs78378222 polymorphism induces a ʻgain-of-function' effect to regulate of TP53 expression via miR-125b. Furthermore, the present study demonstrated that miR-125b is a novel negative regulator of TP53 in vivo, which may be a mechanism of age-associated cataract development. miR-125b may be a potential therapeutic target for the management of age-associated cataracts. Further research in transgenic animals may be able to increase understanding of the importance of miR-125b and confirm the results of the present study.
